Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study-Reference-Cited by-同舟云学术

Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Published:2023-12 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Tutrone Ronald,Saad Fred,George Daniel J.,Tombal Bertrand,Bailen James L.,Cookson Michael S.,Saltzstein Daniel R.,Hanson Sarah,Brown Bruce,Lu Sophia,Fallick Mark,Shore Neal D.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference28 articles.

1. Changing paradigms in management of metastatic castration resistant prostate cancer (mCRPC);Gupta;BMC Urol,2014

2. Gonadotropin-releasing hormone and its analogs;Conn;Annu Rev Med,1994

3. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists;Shore;Prostate Cancer Prostatic Dis,2013

4. Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males;MacLean;J Clin Endocrinol Metab,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testosterone recovery after androgen deprivation therapy;Urologic Oncology: Seminars and Original Investigations;2024-09

2. The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue;Frontiers in Oncology;2024-08-12

3. Testosterone Treatment and Fractures in Men with Hypogonadism;New England Journal of Medicine;2024-04-11